1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
649FFA6081201BA4A85257447004E9AB8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-pharma-competitive-intelligence-data-collection-strategies?opendocument
18
19opendocument
2054.82.99.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Competitive and Business Intelligence Training and Data Collection

Benchmarking Pharma Competitive Intelligence (CI) Data Collection Strategies

ID: 4999


Features:

28 Data Graphics

115 Metrics

44 Narratives


Pages/Slides: 56


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • SPECIAL OFFER
This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines. The research examined a number of areas, including CI information sources and what is being collected. In addition, the study looked at how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results. Managers and executives in CI and CI-related groups can use this report to compare critical elements of their operations with those of leading firms.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Medical Device; Diagnostic


Companies Profiled:
Alcon Laboratories; Takeda Pharmaceuticals; Sanofi-aventis; Pfizer; Roche; Merck; Eli Lilly; Baxter Healthcare; Amgen; Vertex Pharmaceuticals; Theratechnologies; Stiefel; Shire; PDL; King Pharmaceuticals; Indegene Lifesystems; Human Genome Sciences; Ethicon Endo-Surgery Inc.; EMD Serono; ConjuChem Biotechnologies; Centocor; Inc.; Biogen Idec


Study Snapshot

This research was based on benchmark survey data from 24 executives from both large and small pharmaceutical and biotechnology companies. Executives from eight companies participated in the interview portion of the research.

Key topics include:
  • Optimizing Data Collection - People, Processes & Practices
  • Development & Examples of CI Guidelines
  • Managing Expectations
  • Rapid Response Teams
  • Building a Successful CI Function

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.